The drug, trilaciclib, achieved both of its primary endpoints: reductions in the duration and occurrence of Grade 4 neutropenia, a low count of neutrophils, a type of white blood cell.
Read MoreThe chief executive officer of drug development company Fennec Pharmaceuticals saw a 64 percent increase in compensation in 2017, primarily due to receiving a bonus, according to a securities filing,
Read More
Research by a Nobel laureate at the UNC School of Medicine may lead to more precise delivery of anticancer drugs.
Read More
Scientists at the University of North Carolina School of Medicine and North Carolina State University have created an injectable gel-like scaffold that can hold a combination of chemo and immunotherapeutic drugs and deliver them locally to tumors. Researchers say the approach may “Beat back tumor development with limited side-effects.”
Read More
Fennec Pharmaceuticals has been granted fast track designation for its signature drug that targets loss of hearing among children who receive chemotherapy by the FDA.
Read More
